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Abstract
It has been well established that maximum standardized uptake value (SUVmax) for 18F-
fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT)
is clinically useful for evaluating treatment efficacy as well as predicting prognosis of breast
cancer patients. Although SUVmax reflects increased glucose uptake and metabolism
possibly induced by activation of growth factor signaling or TP53 dysfunction, tumor charac-
teristics of SUVmax-high breast cancers remain to be elucidated. For the present study, we
used immunohistochemical staining to investigate expressions of phospho-ribosomal pro-
tein S6 (pS6, downstream molecule of phosphatidyl inositol 3-kinase/Akt/mammalian target
of the rapamycin/S6K pathway) and phosphor-p44/42 mitogen-activated protein kinase
(pMAPK). Expression levels of TP53 and proliferative marker geminin as well as Ki67 were
also examined by means of immunostaining in 163 invasive breast cancers. Cutoff values
were set at 10% for pS6, 20% for pMAPK and TP53, and 4% for geminin. The SUVmax lev-
els were significantly higher in the pS6-positive (p = 0.0173), TP53-positive (p = 0.0207) and
geminin-high cancers (p<0.0001), but there was no significant association between pMAPK
expression levels and SUVmax levels. Multivariable analysis showed that a high geminin
level (odds ratio: 6.497, 95% confidence interval: 2.427–19.202, p = 0.0001) and large
tumor size (6.438, 2.224–20.946, p = 0.0005) were significantly and independently associ-
ated with SUVmax-high. Univariable but not multivariable analysis indicated that Ki67-high
significantly correlated with SUVmax-high. Twenty of 23 (87.0%) breast cancers with tumor
size >2cm and geminin-high showed SUVmax-high, while only 6 of 49 (12.2%) breast
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cancers2cm in size and with low geminin levels were SUVmax-high. In conclusion, we
could determine that breast cancers with a large tumor and a geminin-high rather than Ki67-
high proliferative marker were significantly associated with high levels of SUVmax. These
findings may signify that SUVmax reflects tumor characteristics with high proliferative activ-
ity but not activation of mTOR/S6K and MAPK pathways or increased glucose metabolism
due to dysfunction of TP53.
Introduction
18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/
CT) has been widely used in daily clinical practice as an imaging tool for detecting primary as
well as metastatic breast cancers [1, 2]. In addition to this diagnostic modality, many studies
have demonstrated that the maximum standardized uptake value (SUVmax) on FDG PET has
predictive value for prognosis of operable breast cancers [3–7]. In addition, the value of SUV-
max as a predictive tool for treatment efficacy has been demonstrated in several studies which
found that early reduction of SUVmax resulted in improvement leading to pathological com-
plete response for breast cancers treated with neoadjuvant chemotherapy [8, 9]. Similarly,
early responses determined in terms of SUVmax are reportedly associated with good prognosis
for breast cancer patients treated with neoadjuvant chemotherapy [10, 11].
While the details of the mechanisms of prognostic or predictive values remain to be eluci-
dated, it is speculated that the mechanism of the link between SUVmax and prognosis or treat-
ment efficacy might be related to differences in glucose metabolism in cancer cells [12]. It is
also conceivable that SUVmax reflects glucose uptake in cancer cells and is possibly regulated
by functioning of the glucose transporter (GLUT) present in membrane. Since expression of
GLUT-1 and glucose metabolism are likely to be regulated by activation of growth factor sig-
naling, including the phosphatidyl inositol 3-kinase (PI3K)/Akt/mammalian target of the rapa-
mycin (mTOR) pathway [13, 14] and the mitogen-activated protein kinase (MAPK) pathway
[15], the baseline value of or changes in SUVmax after treatment may reflect activation or sup-
pression of such growth factor signaling. In addition, TP53 has been demonstrated to have a
role in controlling glucose metabolism by downregulation of GLUT expression through the
inhibition of nuclear factor kappa-B kinase [16]. Since TP53 function is frequently lost due to
its mutation occurring in breast cancers [17], it may be speculated that upregulation of SUV-
max levels is related to dysfunction of TP53. Furthermore, it has been reported that higher
uptake of FDG is significantly associated with proliferative ability including increases in
mitotic counts or the Ki67 labeling index [7, 18–20]. Although the existence of connections
between SUVmax levels and activation of growth factor signaling, dysfunction of TP53 or pro-
liferative activity are speculative, hardly any studies concerning this issue in breast cancers
have been reported. Thus, identification and clarification of these characteristics in breast can-
cers with high levels of SUVmax remain a quite important issue in clinical practice.
The aim of the present study was thus to identify factors associated with SUVmax levels
focusing on growth factor signaling, glucose metabolism and proliferative activity. To deter-
mine PI3K/Akt/mTOR and MAPK pathways activation, immunohistochemical staining was
used to evaluate phospho-ribosomal protein S6 (pS6, a downstream molecule of the PI3K/Akt/
mTOR/S6K pathway and phosphorylated by S6K), and phosphor-p44/42 MAPK (pMAPK)
and TP53 for detecting alterations in TP53 proteins as an indicator of glucose metabolism. In
addition, proliferative marker geminin, which is expressed selectively during S to M phases in
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the cell cycle [21], as well as Ki67 was investigated immunohistochemically in order to assess
correlations between proliferative activity and SUVmax levels.
Materials and methods
Recruitment of patients and pathological diagnosis
For this retrospective study, 700 breast cancer patients who underwent surgery at the Hyogo
College of Medicine Hospital between May 2008 and May 2014 were consecutively recruited.
Of these 700 patients, 565 had invasive cancers, for 409 of which preoperative data for 18F-FDG
PET/CT imaging were available, and from 377 of the latter written informed consent was
obtained for participation in this study. For 89 of the 377 cases clinical data were lacking,
including for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth
factor receptor 2 (HER2), nuclear grade or tumor size. Moreover, tumor tissues available were
insufficient due to small tumor size obtained during operation (n = 62) or core needle biopsy
before the start of preoperative therapy (n = 63). Of the remaining 163 samples were selected
for the present study. Samples obtained by core needle biopsy prior to therapy were used for
patients treated with preoperative chemotherapy (n = 31) and endocrine therapy (n = 18) and
intra-operatively resected tissues for the remaining cases. Nuclear grading was done in accor-
dance with the criteria defined by the Japanese Breast Cancer Society classification [22]. Classi-
fication as positive for ER and PgR was based on nuclear staining of these receptors in 1% or
more of the tumor cells. For membrane staining of HER2, a score of 3 was judged to indicate
HER2 positivity, while a score of 2 with positivity for fluorescence in situ hybridization (FISH)
was also classified as HER2-positive.
Details of the staining procedure and antibodies used for staining of ER, PgR, HER2 and
Ki67 were described previously [23]. The Ethics Committee of Hyogo College of Medicine
approved the present study (No. 106) and written informed consent was obtained from all 163
participants.
Immunohistochemical staining procedure
Formalin-fixed, paraffin-embedded tumor tissues obtained intraoperatively or by core needle
biopsy prior to treatment were used for further immunohistochemical staining. To avoid pro-
tein degradation, the tissues were fixed in buffered formalin immediately after resection and
fixed for 24 to 48 hours. For pS6, pMAPK and TP53 staining, we used primary antibodies
D57.2.2E (phospho-S6 ribosomal protein [Ser235/236], rabbit monoclonal antibody; Cell Sig-
naling Technology, Danvers, MA), D13.14.4E (phospho-p44/42 MAPK [Thr202/Tyr204], rab-
bit monoclonal antibody; Cell Signaling Technology) and DO-7 (mouse monoclonal antibody;
Dako, Glostrup, Denmark), respectively. The primary antibodies were diluted 1:200 for pS6
and pMAPK, and 1:100 for TP53. Details of the methods used for immunostaining of pS6,
pMAPK and TP53 have been described in a previous report [23]. For immunohistochemical
staining of geminin, a rabbit anti-Geminin antibody (FL-209, diluted 1:200; Santa Cruz Bio-
technology, Santa Cruz, CA) was used by following a method described elsewhere [24].
Moderate to intense staining in cytoplasm for pS6 and in cytoplasm and nuclei for pMAPK
were evaluated as described in a previous study [23]. Strong nuclear staining was assessed for
TP53 and geminin expression [23, 24]. We counted 500 cancer cells selected in different areas
of the stained lesions. The slides were examined by three of the authors (A.N., A.K. and Y.M.)
who were unaware of the clinical and FDG PET data and in case of discrepancy the samples
were further evaluated in order to reach a consensus.
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18F-FDG PET/CT imaging and determination of SUVmax
Whole-body 18F-FDG PET examinations with a CT scanner (Gemini GXL16; Philips Medical
Systems, Eindhoven, The Netherlands) were performed at Hyogo College of Medicine Hospi-
tal. As described in a previous study [25], 4.0 MBq/kg body weight of 18F-FDG was used for
PET and the scanning image was obtained approximately 60 min after the injection. The
SUV was calculated as the regional radioactivity concentration (Bq/mL)/[injected dose
(Bq)/patient’s weight (g)] in the most intense area of 18F-FDG accumulation (a region of inter-
est: ROI) and the peak SUV in the pixel with the highest count within the ROI was defined as
the SUVmax. The cutoff value for SUVmax-high and -low was set at 3.585, which was deter-
mined in our previous study to identify relapse-free survival in 387 breast cancer patients,
including the cases in the current study [7].
Statistical analysis
Associations between SUVmax levels and clinicopathological characteristics or immunohisto-
chemically determined factors were analyzed with the chi-square test or Fisher’s exact test as
appropriate. Comparison between SUVmax levels and pS6, pMAPK, TP53 or geminin labeling
indices were analyzed with the Spearman correlation coefficient, while SUVmax levels for dif-
ferent groups were compared with the Mann-Whitney test or Kruskal-Wallis test. We used
univariable and multivariable logistic regression analyses to determine the associations
between SUVmax and clinical or immunohistochemically determined factors. The variables
were included in the multivariable model when statistical significance was obtained for a step-
wise forward selection. Odds ratios (ORs) and the corresponding 95% confidence intervals
(CIs) were also calculated. Differences were considered statistically significant for p<0.05.
JMP Pro 11 software (SAS Institute Inc., Cary, NC) was used for all statistical analyses.
Results
Immunohistochemical staining of pS6, pMAPK, TP53, geminin and Ki67
expression levels and correlations of these factors with SUVmax levels
Activation of PI3K/Akt/mTOR and MAPK pathways was evaluated in terms of pS6 and
pMAPK expression levels determined by immunohistochemical staining as represented in
Fig 1(A) and 1(B). Representative positive staining of TP53 and geminin is also shown in
Fig 1(C) and 1(D). The expression levels of geminin and Ki67 were significantly associated
with SUVmax levels (correlation coefficient (ρ): 0.423, p<0.0001; Fig 2D for geminin and ρ:
0.389, p<0.0001; Fig 2E for Ki67). However, no significant associations between SUVmax lev-
els and pS6 (p = 0.07), pMAPK (p = 0.122) or TP53 (p = 0.0869) were found as shown in
Fig 2(A)–2(C). The significant and positive relationship between tumor size and SUVmax lev-
els is shown in Fig 2(F) (ρ: 0.512, p<0.0001).
Determination of optimal cutoff values of pS6, pMAPK, TP53, geminin or
Ki67 for SUVmax levels
In order to identify optimal cutoff values for immunohistochemical markers, we used receiver
operating characteristics curves calculated with the Youden index for the areas under the
curve (AUC). As shown in Fig 3(A)–3(E), cutoffs values were determined as 10% (AUC: 0.624,
p = 0.0767) for pS6, 20% (AUC: 0.569, p = 0.0128) for pMAPK, 20% (AUC: 0.587, p = 0.0445)
for TP53, 4% (AUC: 0.740, p<0.0001) for geminin and 21.5% (AUC: 0.678, p = 0.0009) for
Ki67. Sensitivity and 1-specificity for geminin were 0.696 and 0.286, respectively. These cutoff
values were used for subsequent analyses.
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Correlations between SUVmax levels and clinicopathological or
immunohistochemical factors
Since the optimal cutoff value of SUVmax for relapse-free survival of operated breast cancer
patients was determined at 3.585 in a previous study of ours [7], we used this cutoff value to
divide SUVmax levels into two groups (SUVmax-high: n = 66, SUVmax-low: n = 97). As
shown in Table 1, SUVmax-high cancers were significantly more frequent in cancers with a
large tumor size (>2cm, p<0.0001), nuclear grade 3 (p<0.0001), ER-negative (p = 0.0010),
PgR-negative (p = 0.0013) and high Ki67 expression levels (p<0.0001). SUVmax-high cancers
were detected significantly higher more frequently in pS6-positive, TP53-positive and gemi-
nin-high breast cancers (p = 0.0173, p = 0.0207 and p<0.0001, respectively). On the other
hand, there was only a marginally significant association between SUVmax and pMAPK posi-
tivity (p = 0.0568).
Fig 1. Representative positive immunostaining for pS6 (A), pMAPK (B), TP53 (C) and geminin (D). Staining of cytoplasm (pS6), cytoplasm and
nuclei (pMAPK) and nuclei (TP53 and geminin) was evaluated.
https://doi.org/10.1371/journal.pone.0184508.g001
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Univariable and multivariable analyses for SUVmax
Univariable analysis demonstrated that large tumor size (p<0.0001), lymph node metastasis-
positivity (p = 0.0492), nuclear grade 3 (p<0.0001), ER-negativity (p = 0.0006), PgR-negativity
(p = 0.0014), high levels of Ki67 (p<0.0001), pS6-positivity (p = 0.0045), pMAPK (p = 0.0174),
TP53 (p = 0.0048) and high levels of geminin (p<0.0001) were significantly associated with
high levels of SUVmax (Table 2). Variables which independently predict high levels of SUV-
max were selected based on a stepwise forward regression model. Finally, a multivariable anal-
ysis determined that large tumor size (OR: 6.438, 95% CI: 2.224–20.946, p = 0.0005) and high
levels of geminin (OR: 6.497, 95% CI: 2.427–19.202, p = 0.0001) were independent and signifi-
cant predictive factors (Table 2).
Comparison of SUVmax levels after combination of tumor size and
geminin levels
Since tumor size and geminin expression levels were significant and independent in terms of
likelihood of SUVmax-high levels, these factors were combined for further analysis of 133
Fig 2. Correlations between SUVmax levels and pS6 (A), pMAPK (B), TP53 (C), geminin (D) or Ki67 (E) labeling indices and tumor size (F).
https://doi.org/10.1371/journal.pone.0184508.g002
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breast cancers for which data on geminin were available. Since not enough breast cancer cells
remained after other immunohistochemical examinations had been completed, evaluation of
geminin in the remaining samples was not feasible. As expected, SUVmax levels were signifi-
cantly different for the resultant four groups (p<0.0001, Fig 4). The SUVmax levels were high-
est for the tumor size (T) >2cm/geminin (Gem)-high group (median: 5.75, range: 1.91–12.4)
and lowest for the T2cm/Gem-low group (2.01, 0–8.0). SUVmax levels for the T >2cm/
Gem-low (3.23, 0–14.68) and T2cm/Gem-high (3.63, 0–14.42) showed intermediate levels.
As shown in Table 3, 20 of the 23 T>2cm /Gem-high cancers (87.0%) were SUVmax-high
and only 6 of the 49 T2cm/Gem-low cancers (12.2%) were SUVmax-high when analyzed in
all breast cancers (p<0.0001). Positive associations were consistently recognized in the ER-
positive (p<0.0001) and HER2-negative (p<0.0001), and marginally in the HER2-positive
(p = 0.0828) subsets.
Fig 3. Receiver operating characteristics curves of pS6, pMAPK, TP53, geminin and Ki67 for SUVmax. The cutoff values were determined as
10% for pS6 (A), 20% for pMAPK (B), 20% for TP53 (C), 4% for geminin (D) and 21.5% for Ki67 (E).
https://doi.org/10.1371/journal.pone.0184508.g003
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Table 1. Relationships between SUVmax levels and clinicopathological or immunohistochemical factors of breast cancers.
Characteristics SUVmax-higha
(n = 66)
SUVmax-lowa
(n = 97)
p-value
Menopausal status
Premenopausal 24 (43.6%) 31 (56.4%) 0.559
Postmenopausal 42 (38.9%) 66 (61.1%)
Histological type
No special 64 (41.8%) 89 (58.2%) 0.204
Special 2 (20.0%) 8 (80.0%)
Tumor size
2cm 29 (28.2%) 74 (71.8%) <0.0001
>2cm 37 (61.7%) 23 (38.3%)
Lymph node metastasis
Negative 38 (35.5%) 69 (64.5%) 0.1128
Positive 27 (51.9%) 25 (48.1%)
Not evaluatedb 1 (25.0%) 3 (75.0%)
Nuclear grade
1+2 43 (32.3%) 90 (67.7%) <0.0001
3 23 (76.7%) 7 (23.3%)
Estrogen receptor
Positive 47 (34.6%) 89 (65.4%) 0.0010
Negative 19 (70.4%) 8 (29.6%)
Progesterone receptor
Positive 36 (32.1%) 76 (67.9%) 0.0013
Negative 30 (58.8%) 21 (41.2%)
HER2 status
Negative 53 (37.6%) 88 (62.4%) 0.0648
Positive 13 (59.1%) 9 (40.9%)
Ki67 expression levelsc
Low 24 (26.1%) 68 (73.9%) <0.0001
High 39 (59.1%) 27 (40.9%)
Unknown 3 (60.0%) 2 (40.0%)
pS6 expressiond
Negative 16 (26.7%) 44 (73.3%) 0.0173
Positive 37 (50.7%) 36 (49.3%)
Unknown 13 (43.3%) 17 (56.7%)
pMAPK expressione
Negative 37 (35.6%) 67 (64.4%) 0.0568
Positive 19 (59.4%) 13 (40.6%)
Unknown 10 (37.0%) 17 (63.0%)
TP53 expressione
Negative 40 (34.5%) 76 (65.5%) 0.0207
Positive 22 (61.1%) 14 (38.9%)
Unknown 4 (36.4%) 7 (63.6%)
Geminin expression levelsf
Low 17 (23.6%) 55 (76.4%) <0.0001
High 39 (63.9%) 22 (36.1%)
(Continued )
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Discussion
The findings of this study have confirmed that expression levels of proliferative marker gemi-
nin and tumor size are significantly associated with SUVmax levels in operated breast cancers.
On the other hand, results of the multivariable analysis showed no significant associations
between SUVmax and pS6, pMAPK or TP53 positivity. Since both pS6 and pMAPK expres-
sion levels correlated with activation of, respectively, the PI3K/Akt/mTOR and MAPK path-
ways, it may be speculated that influences on SUVmax levels were not directly regulated solely
by activation of these signaling pathways or metabolic changes possibly derived from TP53
dysfunction. On the basis of the findings of our study, we speculate that higher levels of SUV-
max represent activation of glucose metabolism of breast cancers with large tumor size and
high proliferative activity.
The clinical usefulness of SUVmax for predicting prognosis of early breast cancers has been
well established [3–7]. In addition to its prognostic significance, recent discoveries for SUV-
max have indicated its usefulness for predicting the efficacy of chemotherapies, especially early
response during neoadjuvant chemotherapies [8, 9]. Although the details of the regulating
mechanisms of SUVmax remain to be elucidated, SUVmax seems to reflect uptake of glucose
into cancer cells and its metabolism. The SUVmax levels were significantly higher in our
study’s subsets with a high nuclear grade, ER negativity, PgR negativity and high levels of Ki67.
In spite of the unresolved issues, we were able to demonstrate that large tumor size and high
proliferative activity determined by geminin expression were significant and independent pre-
dictive factors for high levels of SUVmax by multivariable analyses. Large and highly prolifer-
ative cancers may necessitate increased levels of glucose uptake and its metabolism may have
resulted in higher levels of SUVmax. Consistent with our findings, Koo et al. reported that an
increased uptake of 18F-FDG was significantly associated with a high Ki67 index and large
tumor size in primary triple-negative breast cancers [26]. We were the first to demonstrate
that proliferative marker geminin, but not Ki67, is closely linked with SUVmax. The relation-
ship of SUVmax levels with proliferative activity and tumor size appears to be consistent in
both the ER-positive and the HER2-negative subsets (Table 3). Although such a significant
association could not be demonstrated in the ER-negative and the HER2-positive subsets,
this outcome may not be conclusive due to the small number of samples (n = 24 and 21,
respectively).
Interestingly, multivariable analysis showed geminin was superior to Ki67 for predicting
SUVmax levels. Unlike Ki67, which is expressed from the G1 to M phase [27], geminin expres-
sion is detectable in the S, G2, and early M phase [21, 28]. We believe geminin is preferable to
Ki67 evaluating the proliferative activity of breast cancer cells. Significant associations between
SUVmax and expression of phosphorylated Akt and S6 have been identified in renal cell
Table 1. (Continued)
Characteristics SUVmax-higha
(n = 66)
SUVmax-lowa
(n = 97)
p-value
Unknown 10 (33.3%) 20 (66.7%)
a SUVmax (maximum standardized uptake value) high:3.585, low: <3.585.
b axillary examination was not performed.
c low: <21.5%, high:21.5%.
d negative: <10%, positive: 10%.
e negative: <20%, positive: 20%.
f low: <4%, high:4%.
https://doi.org/10.1371/journal.pone.0184508.t001
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cancer [29], as have significant correlations between SUVmax and PI3K and pAkt in laryngeal
[30] and cervical cancers [14]. In contrast to the discoveries of these studies, we could not find
any significant association of SUVmax with either PI3K/Akt/mTOR or MAPK activation as
determined by expression levels of pS6 or pMAPK, respectively. Similar to our result, one
Table 2. Univariable and multivariable analyses of clinical and immunohistochemical factors for SUVmax levels.
n Univariable analysis
OR (95% CI)a
p-value Multivariable analysis
OR (95% CI)a
p-value
Menopausal status
Premenopausal 55 1.00 0.56
Postmenopausal 108 0.822 (0.425–1.595)
T size
2.0cm 103 1.00 <0.0001 1.00 0.0005
>2cm 60 4.105 (2.111–8.170) 6.438 (2.224–20.946)
Lymph node metastasis
Negative 107 1.00 0.0492
Positive 52 1.961 (1.002–3.866)
Nuclear grade
1+2 133 1.00 <0.0001
3 30 6.877 (2.863–18.486)
Estrogen receptor status
Positive 136 1.00 0.0006
Negative 27 4.497 (1.889–11.627)
Progesterone receptor status
Positive 112 1.00 0.0014
Negative 51 3.016 (1.532–6.046)
HER2 status
Negative 141 1.00 0.0585
Positive 22 2.398 (0.969–6.178)
Ki67 levelsb
Low 92 1.00 <0.0001
High 66 4.093 (2.103–8.160)
pS6c
Negative 60 1.00 0.0045
Positive 73 2.826 (1.375–5.997)
pMAPKd
Negative 104 1.00 0.0174
Positive 32 2.647 (1.186–6.073)
TP53d
Negative 116 1.00 0.0048
Positive 36 2.986 (1.394–6.583)
Geminin levelse
Low 72 1.00 <0.0001 1.00 0.0001
High 61 5.735 (2.744–12.467) 6.497 (2.427–19.202)
a Odds ratio (95% confidence interval).
b low: <21.5%, high:21.5%.
c negative: <10%, positive:10%.
d negative: <20%, positive: 20%.
e low: <4%, high:4%.
https://doi.org/10.1371/journal.pone.0184508.t002
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study reported no significant association between p53 status and increased uptake of 18F-FDG
in primary triple-negative breast cancers [26]. Gao et al. reported that chemokine CCL5
increased cell surface expression of GLUT1 and that ATP production mediated through upre-
gulated glucose metabolism resulted in enhanced proliferation of breast cancer cells [31]. We
speculate, therefore, that enhanced SUVmax levels may be induced not by activation of growth
factor signaling, but by other mechanisms including chemokines such as CCL5. This issue
needs to be investigated in future studies of a larger number of samples including breast
cancers.
We cannot exclude the possibility that in the small cancers SUVmax levels were not accu-
rate as compared with actual uptake of FDG because of the partial volume effect [32]. How-
ever, since significant associations between geminin and SUVmax were recognized in cancers
with both small and large tumors (Fig 4 and Table 3), we believe geminin is a useful marker for
predicting SUVmax levels even when the partial volume effect is taken into consideration.
Fig 4. Comparison of SUVmax levels after combination of tumor size and geminin levels. SUVmax
levels for groups with tumor size2cm and geminin-low (G-L),2cm and geminin-high (G-H), >2cm and
geminin-low (G-L) and >2cm and geminin-high (G-H). Boxes represent median values and upper and lower
quartiles.
https://doi.org/10.1371/journal.pone.0184508.g004
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However, the significance of geminin for FDG uptake needs to be investigated by using other
3D parameters such as metabolic tumor volume or total lesion glycolysis. Since SUVmax levels
were measured during examination of clinical practice, we have no data concerning metabolic
tumor volume or total lesion glycolysis. Considering that SUVmax is the most frequently used
in daily practice, we believe that studies which analyzed relationships between SUVmax and
immunohistochemical markers are still useful. Further investigation using these other 3D
parameters needs to be done in future. Another limitation of the present study is the cutoff
value for SUVmax for relapse-free survival of 3.585, which was determined in our previous
study of 387 patients. Usually, cutoff values for SUVmax for predicting patients’ prognosis are
set at 3, 4 or 5.6 [3, 4, 33]. However, it is difficult to directly apply cutoff values determined in
other studies because such SUVmax values vary depending on the institute due to differences
in PET/CT devices used, so that adjustment using phantom models is necessary when using
cutoff values from other institutes. For this reason, we used a cutoff value of 3.585, which was
determined on the basis of the 387 cases in our hospital, including the patients in the current
study so that no adjustment was necessary. Nevertheless, we confirmed that, with different cut-
off values of 3, 4 or 5.6, the significant and independent usefulness of tumor size and geminin
was consistently recognized irrespective of cutoff values (data not shown). Since the results
Table 3. SUVmax levels according to tumor size and geminin expression levels.
Characteristics SUVmax-higha
(n = 56)
SUVmax-lowa
(n = 77)
p-value
All subsets
T >2cm/Gem-highb 20 (87.0%) 3 (13.0%) <0.0001
T >2cm/Gem-low 11 (47.8%) 12 (52.2%)
T2cm/Gem-high 19 (50.0%) 19 (50.0%)
T2cm/Gem-low 6 (12.2%) 43 (87.8%)
ER-positive subset
T >2cm/Gem-high 12 (85.7%) 2 (14.3%) <0.0001
T >2cm/Gem-low 10 (47.6%) 11 (52.4%)
T2cm/Gem-high 16 (50.0%) 16 (50.0%)
T2cm/Gem-low 2 (4.8%) 40 (95.2%)
ER-negative subset
T >2cm/Gem-high 8 (88.9%) 1 (11.1%) 0.311
T >2cm/Gem-low 1 (50.0%) 1 (50.0%)
T2cm/Gem-high 3 (50.0%) 3 (50.0%)
T2cm/Gem-low 4 (57.1%) 3 (42.9%)
HER2-negative subset
T >2cm/Gem-high 13 (92.9%) 1 (7.1%) <0.0001
T >2cm/Gem-low 8 (44.4%) 10 (55.6%)
T2cm/Gem-high 18 (48.6%) 19 (51.4%)
T2cm/Gem-low 5 (11.6%) 38 (88.4%)
HER2-positive subset
T >2cm/Gem-high 7 (77.8%) 2 (22.2%) 0.0828
T >2cm/Gem-low 3 (60.0%) 2 (40.0%)
T2cm/Gem-high 1 (100%) 0 (0%)
T2cm/Gem-low 1 (16.7%) 5 (83.3%)
a SUVmax (maximum standardized uptake value) high:3.585, low: <3.585.
b geminin (Gem) low: <4%, high:4%.
https://doi.org/10.1371/journal.pone.0184508.t003
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presented here were obtained in a retrospective, single-institute study and the sample size was
not sufficiently large, they need to be validated in future prospective studies to deal with the
issues mentioned above with a large number of patients.
In conclusion, we found that proliferative marker geminin and tumor size were signifi-
cantly associated with SUVmax levels in operated breast cancers. Since our findings did not
show any significant associations of SUVmax with pS6, pMAPK or TP53 status by the multi-
variable analysis, we speculate that activation of the PI3K/Akt/mTOR and MAPK pathways or
increased glucose metabolism due to TP53 dysfunction may not be the only factors to influ-
ence SUVmax levels. The finding of the present study that SUVmax levels reflect proliferative
activity of breast cancers may prove to be useful for a better understanding of the clinical sig-
nificance of SUVmax as a prognostic as well as a predictive indicator.
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